Becton Dickinson (WBO:BDX) FFO


WBO:BDX Becton Dickinson & Co WBO:BDX
63 GF Score
Price €133.90
GF Value €163.20
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Becton Dickinson FFO?

FFO (Funds from operations) only applies to REITs.

WBO:BDX
63GF Score
Becton Dickinson & Co WBO:BDX
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Becton Dickinson (WBO:BDX) Overvalued in 2026?

Based on GuruFocus' analysis, Becton Dickinson stock appears to be undervalued. The current stock price of €133.90 is trading 18% below its estimated GF Value™ of €163.20. GuruFocus considers Becton Dickinson to be Modestly Undervalued.

Key valuation signals for WBO:BDX:

  • FFO:
  • GF Value™: €163.20 vs. price of €133.90 (18% below fair value)
  • GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the WBO:BDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Becton Dickinson Business Description

Address 1 Becton Drive, Franklin Lakes, NJ, USA, 07417-1880
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
63GF Score

Get the complete analysis for WBO:BDX

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€133.90
Price
€163.20
GF Value